Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-‘749) and its long-term systemic safety profile was consistent with…Read More
You might also be interested in reading Kaspa (KAS) To Hit $3 In Explosive Bull Run, Expert Predicts 2650% Surge.